Free Trial
→ Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) (From InvestorPlace) (Ad)tc pixel Free SABSW Stock Alerts

SAB Biotherapeutics (SABSW) Competitors

$0.01 0.00 (-12.68%)
Closing price 06/5/2026 03:59 PM Eastern
Extended Trading
$0.01 0.00 (-10.48%)
As of 06/5/2026 04:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

SABSW vs. AIMDW, ALVOW, ARAV, ACABW, and BFRIW

Should you buy SAB Biotherapeutics stock or one of its competitors? MarketBeat compares SAB Biotherapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with SAB Biotherapeutics include Ainos (AIMDW), Alvotech (ALVOW), Aravive (ARAV), Atlantic Coastal Acquisition Corp. II (ACABW), and Biofrontera (BFRIW). These companies are all part of the "pharmaceutical products" industry.

How does SAB Biotherapeutics compare to Ainos?

Ainos (NASDAQ:AIMDW) and SAB Biotherapeutics (NASDAQ:SABSW) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, media sentiment, valuation, earnings, institutional ownership, analyst recommendations and dividends.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ainos$18.11KN/AN/AN/AN/A
SAB BiotherapeuticsN/AN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
AinosN/A N/A N/A
SAB Biotherapeutics N/A N/A N/A

In the previous week, Ainos had 1 more articles in the media than SAB Biotherapeutics. MarketBeat recorded 1 mentions for Ainos and 0 mentions for SAB Biotherapeutics. Ainos' average media sentiment score of 0.98 beat SAB Biotherapeutics' score of 0.00 indicating that Ainos is being referred to more favorably in the media.

Company Overall Sentiment
Ainos Positive
SAB Biotherapeutics Neutral

Summary

Ainos beats SAB Biotherapeutics on 3 of the 3 factors compared between the two stocks.

How does SAB Biotherapeutics compare to Alvotech?

Alvotech (NASDAQ:ALVOW) and SAB Biotherapeutics (NASDAQ:SABSW) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alvotech$586.32MN/AN/AN/AN/A
SAB BiotherapeuticsN/AN/AN/AN/AN/A

In the previous week, Alvotech's average media sentiment score of 0.00 equaled SAB Biotherapeutics'average media sentiment score.

Company Overall Sentiment
Alvotech Neutral
SAB Biotherapeutics Neutral

Company Net Margins Return on Equity Return on Assets
AlvotechN/A N/A N/A
SAB Biotherapeutics N/A N/A N/A

Summary

Alvotech beats SAB Biotherapeutics on 1 of the 1 factors compared between the two stocks.

How does SAB Biotherapeutics compare to Aravive?

SAB Biotherapeutics (NASDAQ:SABSW) and Aravive (NASDAQ:ARAV) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

Company Net Margins Return on Equity Return on Assets
SAB BiotherapeuticsN/A N/A N/A
Aravive N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SAB BiotherapeuticsN/AN/AN/AN/AN/A
AraviveN/AN/AN/A-$0.90N/A

In the previous week, SAB Biotherapeutics' average media sentiment score of 0.00 equaled Aravive'saverage media sentiment score.

Company Overall Sentiment
SAB Biotherapeutics Neutral
Aravive Neutral

35.8% of Aravive shares are owned by institutional investors. 60.4% of Aravive shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Aravive beats SAB Biotherapeutics on 2 of the 2 factors compared between the two stocks.

How does SAB Biotherapeutics compare to Atlantic Coastal Acquisition Corp. II?

SAB Biotherapeutics (NASDAQ:SABSW) and Atlantic Coastal Acquisition Corp. II (NASDAQ:ACABW) are both pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, valuation, earnings, profitability, media sentiment, institutional ownership and dividends.

Company Net Margins Return on Equity Return on Assets
SAB BiotherapeuticsN/A N/A N/A
Atlantic Coastal Acquisition Corp. II N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SAB BiotherapeuticsN/AN/AN/AN/AN/A
Atlantic Coastal Acquisition Corp. IIN/AN/AN/AN/AN/A

In the previous week, SAB Biotherapeutics' average media sentiment score of 0.00 equaled Atlantic Coastal Acquisition Corp. II'saverage media sentiment score.

Company Overall Sentiment
SAB Biotherapeutics Neutral
Atlantic Coastal Acquisition Corp. II Neutral

Summary

SAB Biotherapeutics and Atlantic Coastal Acquisition Corp. II tied by winning 0 of the 0 factors compared between the two stocks.

How does SAB Biotherapeutics compare to Biofrontera?

SAB Biotherapeutics (NASDAQ:SABSW) and Biofrontera (NASDAQ:BFRIW) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, valuation, earnings, profitability, media sentiment, institutional ownership and dividends.

Company Net Margins Return on Equity Return on Assets
SAB BiotherapeuticsN/A N/A N/A
Biofrontera N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SAB BiotherapeuticsN/AN/AN/AN/AN/A
Biofrontera$43.20MN/AN/AN/AN/A

In the previous week, SAB Biotherapeutics' average media sentiment score of 0.00 equaled Biofrontera'saverage media sentiment score.

Company Overall Sentiment
SAB Biotherapeutics Neutral
Biofrontera Neutral

Summary

Biofrontera beats SAB Biotherapeutics on 1 of the 1 factors compared between the two stocks.

Get SAB Biotherapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for SABSW and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SABSW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SABSW vs. The Competition

Export
MetricSAB BiotherapeuticsBiotechnology IndustryMedical SectorNASDAQ Exchange
Market CapN/A$460.38M$6.68B$11.99B
Dividend YieldN/A3.87%2.67%5.55%
P/E RatioN/A3.1524.0323.62
Price / SalesN/A6,606.57519.33112.45
Price / CashN/A13.1342.2354.60
Price / BookN/A83.479.736.35
Net IncomeN/A-$96.07M$3.57B$337.59M
7 Day PerformanceN/A-1.89%-1.27%-2.52%
1 Month PerformanceN/A1.18%1.39%-0.03%
1 Year PerformanceN/A64.52%23.95%25.34%

SAB Biotherapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SABSW
SAB Biotherapeutics
N/A$0.01
-12.7%		N/A-69.9%$0.00N/AN/A140
AIMDW
Ainos
N/A$0.14
+25.6%		N/A+13.7%$0.00$18.11KN/A40
ALVOW
Alvotech
N/A$0.17
-31.1%		N/A-92.7%$0.00$586.32MN/A4
ARAV
Aravive
N/A$0.04
flat		N/AN/A$0.00N/AN/A20
ACABW
Atlantic Coastal Acquisition Corp. II
N/A$0.00
+13.6%		N/AN/A$0.00N/AN/A15

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:SABSW) was last updated on 6/7/2026 by MarketBeat.com Staff.
From Our Partners
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
June 12: $100 Turns Into $100,000?
The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla,...
Brownstone Research | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
SpaceX just filed. The clock is ticking.
Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...
The Oxford Club | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
SpaceX will mint billionaires. You won't be one of them.
By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...
Behind the Markets | Sponsoredtc pixel